Safety and Efficacy Study of S-309309 in Obese Adults
Completed · Phase 2 · NCT05925114
Conditions: Obesity
At a glance
- Research payments reported, 2025
- $261,066
- U.S. investigators named
- 23
- Sites paid
- 18
- Planned or actual enrollment
- 365
About the trial
- Sponsor
- Shionogi
- Tested
- S-309309 (drug), Placebo (drug)
- Dates
- Started 2023-06-21; completion 2024-05-17
- Results posted
- Not yet
The primary objective of this study is to understand the efficacy of S-309309 on the body weight of obese adults.
From ClinicalTrials.gov, last updated 2025-04-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Shionogi Inc reported $261,066 in research payments for this study in 2025 (59 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kenneth Steil, D.O. Dermatology · Scottsdale, AZ
- David Guzman, M.D. Internal Medicine · Los Angeles, CA
- Rizwana Mohseni, D.O. Family Medicine · Lake Forest, CA
- Joseph Soufer, M.D. Internal Medicine · Waterbury, CT
- Mark E. Kutner, MD Internal Medicine · Miami, FL
- Rafael O. Nunez, MD Internal Medicine · West Palm Beach, FL
- Steven B. Leichter, M.D. Endocrinology & Diabetes · Columbus, GA
- Manish Jain, M.D. Rheumatology · Chicago, IL
- Harold E. Bays, MD Endocrinology & Diabetes · Louisville, KY
- Husna Baksh, M.D. Internal Medicine · Silver Spring, MD
- Anthony R. Barber, MD Endocrinology & Diabetes · Hickory, NC
- Alexander Ryan, D.O. Internal Medicine · Lincoln, NE
- Samer Nakhle, MD Endocrinology & Diabetes · Las Vegas, NV
- Michael B. Butcher, M.D. Family Medicine · Cincinnati, OH
- Charles Lunn JR. Family Medicine · Oklahoma City, OK
- Martin Basaldua, M.D. Family Medicine · Kingwood, TX
- Mark S. Kipnes, MD Endocrinology & Diabetes · San Antonio, TX
- Dan Lender, MD Endocrinology & Diabetes · Rockwall, TX
- Veena R. Watwe, M.D. Endocrinology & Diabetes · Houston, TX
- John M. Hemmersmeier, MD Family Medicine · Ogden, UT
- Jared B. Probst, MD Family Medicine · Salt Lake City, UT
- Nabil S. Andrawis, M.D. Internal Medicine · Burke, VA
- James R. Clark, MD Internal Medicine · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- 3sync LLC $44,013
- Velocity Clinical Research Inc $43,325
- Cognitive Clinical Trials LLC $34,412
- Suncoast Research Group LLC $25,394
- Be Well Clinical Studies LLC $20,718
- Elias Research Associates LLC $13,124
- Catalina Research Institute $12,116
- Javara Inc $10,398
- Lucas Research Inc $10,027
- Burke Internal Medicine and Re $7,901
- Palm Research Center Inc $7,732
- Great Lakes Clinical Trials Ll $7,300
- Columbus Regional Research Institute $6,056
- Clinical Research Solution LLC $5,215
- Lynn Health Science Institute $4,729
- Charlottesville Medical Resear $4,000
- Diabetes and Glandular Disease Clinic PA $3,450
- Chase Medical Research LLC $1,156
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.